EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

Recruiting Phase 1 Interventional Study
EBV-Related Hodgkin Lymphoma EBV-Related Lymphoproliferative Disorder EBV Related Non-Hodgkin's Lymphoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
52 (estimated)
Sponsor
Baylor College of Medicine · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study is for patients that have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease which has come back or has not gone away after treatment, including the best treatment the investigators know for these diseases. Some patients with Lymphoma or T/NK-lymphoproliferative disease show signs of virus that is sometimes called Epstein Barr virus…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
1. INCLUSION CRITERIA AT TIME OF PROCUREMENT 1. Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non Hodgkin's Lymphoma, (regardless of the histological subtype) or EBV (associated)- T/NK-lymphoproliferative disease who may subsequently be eligible for the treatment componen…
Contacts

Bilal Omer, MD

832-824-6855

bomer@bcm.edu

CONTACT

Dustin McFadden

832-824-3855

Dustin.McFadden@bcm.edu

CONTACT